Atopic dermatitis: abrocitinib clears skin, eases symptoms in phase 2b trial

  • Gooderham MJ & al.
  • JAMA Dermatol
  • 2 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The oral Janus kinase 1 (JAK1) inhibitor abrocitinib is associated with clinical improvement compared with placebo in patients with moderate to severe atopic dermatitis, according to results from a phase 2b trial.

Why this matters

  • Further therapy options are needed for atopic dermatitis, which is common and associated with substantial patient and caregiver burden.

Key results

  • Patients receiving abrocitinib had higher rates of improvement (clear/almost clear on Investigator’s Global Assessment scale with improvement ≥2 grades) compared with patients receiving placebo (44.5% for patients receiving 200 mg, 27.8% for patients receiving 100 mg, 6.3% for patients receiving placebo; P<.001 for both abrocitinib doses compared with placebo>
  • Abrocitinib 200 mg and abrocitinib 100 mg were associated with greater reductions in the Eczema Area and Severity Index (82.6% and 59.0%, respectively) compared with placebo (35.2%; P<.001 and p=".009," respectively>
  • 68.9% of patients experienced adverse events; 3.4% experienced serious treatment-emergent adverse events.

Study design

  • 267 patients with moderate to severe atopic dermatitis were randomly assigned 1:1:1:1:1 to receive abrocitinib 200, 100, 30, or 10 mg, or placebo for 12 weeks and analysed for efficacy and safety.
  • Funding: Pfizer Inc.

Limitations

  • Short trial duration.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit